Disc raises $225.5m as it eyes approval of rare skin disorder drug
Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA earlier this week.
Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA earlier this week.
What's Your Reaction?
